$VKTX
Viking Therapeutics, Inc. Stock $vktx

$vktx Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000119312515291529 Filed on August 14, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.780M	$1.530M	$510.0K
YoY Change	394.44%	200.0%	5000.0%
% of Gross Profit
Research & Development	$2.508M	$1.101M	$21.24M
YoY Change	217.41%	-94.82%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$4.288M	$2.627M	$21.76M
YoY Change	272.89%	-87.93%	108678.16%
Operating Profit	-$4.288M	-$2.627M	-$21.76M
YoY Change		-87.93%
Interest Expense	-$10.31K	-$29.81K	-$9.518K
YoY Change	-58.81%	213.24%	-4.82%
% of Operating Profit
Other Income/Expense, Net	-$448.3K	-$5.238M	-$1.027M
YoY Change	-150.53%	409.97%
Pretax Income	-$4.740M	-$7.870M	-$22.78M
YoY Change	1723.08%	-65.45%	113800.0%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$4.737M	-$7.865M	-$22.78M
YoY Change	1709.22%	-65.48%	113813.94%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$529.6K	-$1.074M	-$2.634M
COMMON SHARES
Basic Shares Outstanding	9.783M shares	9.783M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.50M	$21.70M	$900.0K
YoY Change		2311.11%
Cash & Equivalents	$2.140M	$9.497M	$891.5K
Short-Term Investments	$15.30M	$12.20M
Other Short-Term Assets	$1.400M	$600.0K	$0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$18.93M	$22.27M	$900.0K
YoY Change		2374.41%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$80.00K	$0.00	$1.100M
YoY Change		-100.0%
Total Long-Term Assets	$80.00K	$0.00	$1.100M
YoY Change		-100.0%
TOTAL ASSETS
Total Short-Term Assets	$18.93M	$22.27M	$900.0K
Total Long-Term Assets	$80.00K	$0.00	$1.100M
Total Assets	$19.01M	$22.27M	$2.000M
YoY Change		1013.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$401.7K	$1.008M	$1.400M
YoY Change		-27.98%
Accrued Expenses	$1.300M	$200.0K	$22.20M
YoY Change		-99.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.900M	$1.700M	$300.0K
YoY Change		466.67%
Total Short-Term Liabilities	$5.723M	$4.876M	$24.00M
YoY Change		-79.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$300.0K
YoY Change		-100.0%
Other Long-Term Liabilities	$0.00	$0.00	$1.000M
YoY Change		-100.0%
Total Long-Term Liabilities	$19.15K	$0.00	$1.300M
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.723M	$4.876M	$24.00M
Total Long-Term Liabilities	$19.15K	$0.00	$1.300M
Total Liabilities	$5.742M	$4.876M	$25.30M
YoY Change		-80.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$40.45M	-$35.72M
YoY Change
Common Stock	$53.73M	$29.25M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.27M	$17.39M	-$23.30M
YoY Change
Total Liabilities & Shareholders Equity	$19.01M	$22.27M	$2.000M
YoY Change		1013.48%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$4.737M	-$7.865M	-$22.78M
YoY Change	1709.22%	-65.48%	113813.94%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.400M	-$1.620M	-$440.0K
YoY Change	457.38%	268.18%	4300.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$3.260M	-$12.17M	$0.00
YoY Change
Cash From Investing Activities	-$3.260M	-$12.17M	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-710.0K	22.97M	1.250M
YoY Change	-236.54%	1737.6%	468.18%
NET CHANGE
Cash From Operating Activities	-3.400M	-1.620M	-440.0K
Cash From Investing Activities	-3.260M	-12.17M	0.000
Cash From Financing Activities	-710.0K	22.97M	1.250M
Net Change In Cash	-7.370M	9.180M	810.0K
YoY Change	8088.89%	1033.33%	285.71%
FREE CASH FLOW
Cash From Operating Activities	-$3.400M	-$1.620M	-$440.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	168000
CY2014Q1	us-gaap	Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance	1000000	shares
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9783312	shares
CY2015Q2	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	633810	shares
CY2015Q2	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	366190	shares
CY2014Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	21315074
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	891480
CY2014Q2	vktx	Accrued License Fees Current AccruedLicenseFeesCurrent	19865863
CY2014Q2	vktx	Debt Conversion Feature Liability Current DebtConversionFeatureLiabilityCurrent	58742
CY2014Q2	vktx	Debt Conversion Feature Liability Noncurrent DebtConversionFeatureLiabilityNoncurrent	1390469
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	347894	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.00
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.87
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9783312	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.87
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	51500	shares
CY2015Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	15	Securities
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9783312	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.49
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	347894	shares
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	53123840
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	119647
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	17393539
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-12461
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	115
CY2015Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1670509
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1008277
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35717938
CY2015Q2	us-gaap	Liabilities Liabilities	4876110
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22269649
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	98
CY2015Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1956566
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4876110
CY2015Q2	us-gaap	Interest Payable Current InterestPayableCurrent	121111
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	20990292
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	61566
CY2015Q2	us-gaap	Assets Assets	22269649
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	12576
CY2015Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	20990292
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	60
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22517082
CY2015Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	12162251
CY2015Q2	us-gaap	Assets Current AssetsCurrent	22269649
CY2015Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	3070486
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	610198
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9497200
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	21002753
CY2015Q2	vktx	Unpaid Deferred Initial Public Offering Costs UnpaidDeferredInitialPublicOfferingCosts	-709006
CY2015Q2	vktx	Convertible Notes Payable Discount Noncurrent ConvertibleNotesPayableDiscountNoncurrent	0
CY2015Q2	vktx	Debt Conversion Feature Liability Current DebtConversionFeatureLiabilityCurrent	1956566
CY2015Q2	vktx	Debt Conversion Feature Liability Noncurrent DebtConversionFeatureLiabilityNoncurrent	1956566
CY2015Q2	vktx	Convertible Notes Payable Discount Current ConvertibleNotesPayableDiscountCurrent	829491
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	179619
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6000000	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6000000	shares
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2654583
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	12866
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	380257
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-22128531
CY2014Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1264114
CY2014Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	304274
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1830724
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22141457
CY2014Q4	us-gaap	Liabilities Liabilities	25171665
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3043134
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	77222
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	0
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	775
CY2014Q4	us-gaap	Assets Assets	3043134
CY2014Q4	us-gaap	Assets Current AssetsCurrent	773684
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	2268675
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17827
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	755857
CY2014Q4	vktx	Accrued License Fees Current AccruedLicenseFeesCurrent	19865863
CY2014Q4	vktx	Convertible Notes Payable Discount Noncurrent ConvertibleNotesPayableDiscountNoncurrent	1235886
CY2014Q4	vktx	Debt Conversion Feature Liability Current DebtConversionFeatureLiabilityCurrent	58742
CY2014Q4	vktx	Debt Conversion Feature Liability Noncurrent DebtConversionFeatureLiabilityNoncurrent	1390469
CY2014Q4	vktx	Convertible Notes Payable Discount Current ConvertibleNotesPayableDiscountCurrent	6076
CY2015Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	282	shares
CY2015Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-540635
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	2008675	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	5718232	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.20
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2572919	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3709557	shares
	us-gaap	Net Income Loss NetIncomeLoss	-23011729
	us-gaap	Revenues Revenues	0
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-12094
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	27926
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21965369
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1046360
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23011729
	us-gaap	Share Based Compensation ShareBasedCompensation	1953
	us-gaap	Operating Expenses OperatingExpenses	21965369
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1252496
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21291640
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	44923
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	2496
	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	711861
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4451000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	673729
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	66982
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	248262
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1250000
	vktx	Increase Decrease In Accrued License Fees IncreaseDecreaseInAccruedLicenseFees	22128979
	vktx	Change In Fair Value Of Accrued License Fees ChangeInFairValueOfAccruedLicenseFees	959363
	vktx	Change In Fair Value Of Debt Conversion Features ChangeInFairValueOfDebtConversionFeatures	7921
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2031650
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M6D
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1563788	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0169	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	7275523	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.38
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1304833	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001607678
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2012-09-24
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y10M10D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y10M6D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	282	shares
	us-gaap	Additional Cash And Cash Equivalent Related Text AdditionalCashAndCashEquivalentRelatedText	Three months or less
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <i>Concentration of Credit Risk</i></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.852	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.87
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	Viking Therapeutics, Inc.
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	347894	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.87
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to determining the fair value of the debt conversion feature liability and accounting for certain commitments. Actual results could differ from those estimates.</p> </div>
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Delaware
	dei	Trading Symbol TradingSymbol	VKTX
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5711735	shares
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-12174067
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y10M10D
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	22947060
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1239875
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	12174067
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12461
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13588942
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0
	us-gaap	Share Based Compensation ShareBasedCompensation	1472412
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	4130
	us-gaap	Operating Expenses OperatingExpenses	3087954
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2152
	us-gaap	Net Income Loss NetIncomeLoss	-13576481
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	418412
	us-gaap	Revenues Revenues	0
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-65067
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	591595
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2029142
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3087954
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10488527
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25392500
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	191987
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	-38
	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8741343
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1472412000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1848079
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	412471
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	44437
	vktx	Issuance Of Common Stock To Consultant IssuanceOfCommonStockToConsultant	28760
	vktx	Warrant Expiration Date WarrantExpirationDate	2022-04-28
	vktx	Sublease Term Commenced End Date SubleaseTermCommencedEndDate	2018-09-30
	vktx	Conversion Of Notes Payable ConversionOfNotesPayable	456412
	vktx	Sublease Agreement Date SubleaseAgreementDate	2015-07-07
	vktx	Description Of Warrant DescriptionOfWarrant	The warrant is exercisable for cash or on a cashless basis at a per share exercise price equal to $10.00 commencing on April 28, 2016, one year following the date of the prospectus filed with the SEC relating to the IPO, and expiring on April 28, 2020. The representative (or permitted assignees) agreed not to sell, transfer, assign, pledge or hypothecate the warrant or the shares of common stock underlying the warrant, or to engage in any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the warrant or the underlying shares of common stock until October 25, 2015. In addition, the warrant provides for registration rights upon request, under certain circumstances. The piggyback registration right provided in connection with the warrant will terminate on April 28, 2022.
	vktx	Change In Fair Value Of Accrued License Fees ChangeInFairValueOfAccruedLicenseFees	9381848
	vktx	Change In Fair Value Of Debt Conversion Features ChangeInFairValueOfDebtConversionFeatures	629141
	vktx	Anniversary Closing Date Of Initial Public Offering AnniversaryClosingDateOfInitialPublicOffering	2016-05-04
	vktx	Sublease Term Commenced Date SubleaseTermCommencedDate	2015-08-01
	vktx	Stock Issued In Lieu Of License Fee StockIssuedInLieuOfLicenseFee	29247711
CY2014Q1	us-gaap	Deferred Compensation Arrangement With Individual Exercise Price DeferredCompensationArrangementWithIndividualExercisePrice	0.01
CY2014Q1	vktx	Number Of Tranches NumberOfTranches	2	Tranche
CY2015Q2	vktx	Shares Repurchase Price Per Share SharesRepurchasePricePerShare	0.00001
CY2014Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1778243	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	6000000	shares
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.40
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4221757	shares
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-22782787
CY2014Q2	us-gaap	Revenues Revenues	0
CY2014Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-9518
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-21755631
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1027156
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22782787
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	21755631
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21241640
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3547000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	513991
CY2014Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	60603
CY2014Q2	vktx	Change In Fair Value Of Accrued License Fees ChangeInFairValueOfAccruedLicenseFees	959363
CY2014Q2	vktx	Change In Fair Value Of Debt Conversion Features ChangeInFairValueOfDebtConversionFeatures	-2328
CY2015Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1205169	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	8537030	shares
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.07
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7331861	shares
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-7865066
CY2015Q2	us-gaap	Revenues Revenues	0
CY2015Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-29814
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2626914
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5238152
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12461
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7877527
CY2015Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	2626914
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1100906
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1471509000
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1526008
CY2015Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	240515
CY2015Q2	vktx	Change In Fair Value Of Accrued License Fees ChangeInFairValueOfAccruedLicenseFees	4421338
CY2015Q2	vktx	Change In Fair Value Of Debt Conversion Features ChangeInFairValueOfDebtConversionFeatures	546485

Files In Submission

Name	View Source	Status
0001193125-15-291529-index-headers.html	Edgar Link	pending
0001193125-15-291529-index.html	Edgar Link	pending
0001193125-15-291529.txt	Edgar Link	pending
0001193125-15-291529-xbrl.zip	Edgar Link	pending
d52828d10q.htm	Edgar Link	pending
d52828dex311.htm	Edgar Link	pending
d52828dex312.htm	Edgar Link	pending
d52828dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vktx-20150630.xml	Edgar Link	completed
vktx-20150630.xsd	Edgar Link	pending
vktx-20150630_cal.xml	Edgar Link	unprocessable
vktx-20150630_def.xml	Edgar Link	unprocessable
vktx-20150630_lab.xml	Edgar Link	unprocessable
vktx-20150630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VKTX
Viking Therapeutics, Inc. Stock $vktx

2015 Q3 Form 10-Q Financial Statement

#000119312515291529 Filed on August 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VKTX Viking Therapeutics, Inc. Stock $vktx

2015 Q3 Form 10-Q Financial Statement

#000119312515291529 Filed on August 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VKTX
Viking Therapeutics, Inc. Stock $vktx